← Markets

MBX Biosciences, Inc. Common Stock

MBX · NASDAQ

Market closed$62.92$4.60 (+7.89%)After hours $63.98 · +1.69%

Key statistics

Previous close$58.32
Open$56.67
Day high$63.08
Day low$55.42
52-week high$66.55
52-week low$9.63
Market cap2.11B
Volume884.66K
Average volume840.31K
P/E ratio-28.47
Forward P/E—
EPS-2.21
Dividend yield0.00%

Market context

Why it moved

MBX Biosciences shares surged sharply after the company reported positive clinical study data, driving strong investor enthusiasm and a significant rally in the stock.

SubstackInvesting.comHallrenderFacebookFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026MBX Biosciences surged nearly 8% on Friday, recovering sharply from the prior session's steep sell-off triggered by the sudden departure of co-founder and CEO Kent Hawryluk, with Steve Hoerter stepping in as Chairman and CEO. Analyst confidence appeared to reassert itself, with LifeSci Capital maintaining a Buy rating and $91 price target, citing pipeline visibility and reaffirmed trial timelines — while the stock continues to trade well above its 50-day moving average of $42.53 and holds an 84%+ year-to-date gain amid broader biotech sector optimism.

7.8875

July 17, 2026MBX Biosciences shares fell nearly 4% as investors digested a significant leadership shake-up — the departure of CEO Kent Hawryluk, replaced by executive chairman Steven Hoerter effective July 13 — which extended a sharp ~9% selloff from the prior session. Despite the near-term volatility, institutional interest remains broadly supportive, with Candriam, Wellington Management, Vanguard, and others recently adding to positions, and analyst price targets ranging from $70 to $88, well above current levels. Shares are partially recovering in after-hours trading, up roughly 1.6%, as the broader healthcare sector found a tailwind from UnitedHealth Group's strong Q2 earnings beat and raised guidance on July 16.

-3.8893

July 16, 2026MBX Biosciences surged over 7% on above-average volume, even as a Quiverquant alert flagged an intraday dip earlier in the session, with the stock closing near its day high of $60.70. The rally comes amid notable leadership changes announced July 13 — CEO Kent Hawryluk departed and was replaced by executive chairman Steven Hoerter — alongside growing institutional interest from Wellington Management, Candriam, and others. Analysts remain broadly bullish with price targets ranging up to $88, while the broader healthcare sector and S&P 500 were supported by a soft CPI reading.

7.2186

July 15, 2026MBX Biosciences tumbled after the company announced an unexpected CEO departure, with founder and CEO Kent Hawryluk stepping down effective July 13 and executive chairman Steven Hoerter stepping in as his replacement. The leadership shake-up — alongside the concurrent naming of a new CFO — rattled investors, driving shares down roughly 5.75% on nearly double the average trading volume. Selling was amplified by broader healthcare sector headwinds, as XLV declined on the day amid a mixed market backdrop. In after-hours trading, shares partially recovered, climbing nearly 2%, suggesting some investors viewed the selloff as an overreaction given the company's strong institutional backing and a Moderate Buy consensus.

-5.7462

July 14, 2026MBX Biosciences shares fell and extended their decline in after-hours trading, weighed down by a surprise leadership shakeup after the company announced CEO Kent P. Hawryluk's departure, effective July 13, alongside the naming of new CEO and CFO replacements. The stock closed down modestly during regular hours amid a broadly risk-off session driven by renewed U.S.-Iran military tensions, but tumbled sharply after hours as investors digested the executive transition. This comes as analyst sentiment remains constructive—consensus sits at Moderate Buy with a ~$60 target—and institutional investors including Candriam, Wellington, and Vanguard recently added to positions.

-1.6544

July 11, 2026MBX Biosciences tumbled sharply, bucking a broadly positive biotech sector backdrop, as investors digested a notable pullback from recent highs reached just days prior. The decline came despite a constructive environment for biotech — XLV hit record highs this month and analysts like Jim Cramer have called biotech the hottest group in the market. The selling pressure may reflect profit-taking after MBX hit an all-time high near $59.55 earlier in the week, alongside investor concern over the broader impact of Medicaid cuts from the One Big Beautiful Bill Act, which analysts warn could dampen biotech revenue projections. Notably, both FMR LLC (11.2%) and Wellington Management (10.46%) disclosed large passive stakes via amended 13G filings, signaling continued institutional confidence in the stock's long-term thesis around its canvuparatide and obesity drug candidate MBX-4291 pipeline.

-7.0918

July 10, 2026MBX Biosciences surged to a new all-time high, closing near its intraday peak of $66.55, as a confluence of institutional conviction and sector momentum drove the stock sharply higher. Major institutional holders FMR LLC (Fidelity) and Wellington Management disclosed amended 13G filings revealing stakes of 11.2% and 10.46%, respectively, signaling strong passive institutional backing. The move also comes amid a broad biotech rally, with Jim Cramer calling the sector "the hottest group in the market" and analysts flagging an M&A wave under a more favorable FDA backdrop — dynamics that benefit MBX given its differentiated pipeline across hypoparathyroidism (canvuparatide), obesity (MBX-4291), and post-bariatric hypoglycemia (imapextide).

6.4302

July 9, 2026MBX Biosciences edged down slightly after hitting a new all-time high intraday at $64.32, extending a remarkable 350%+ one-year run fueled by strong clinical momentum across its pipeline. Investor interest has intensified following two major institutional ownership disclosures today — FMR LLC (Fidelity) reporting an 11.2% stake and Wellington Management disclosing a 10.46% stake — signaling deep institutional conviction. The backdrop is further supported by Jim Cramer calling biotech 'the hottest group in the market' amid a wave of M&A activity, and the healthcare sector posting its strongest relative performance in over 15 years.

-0.4194

Simply Wall Street · July 17, 2026Is MBX Biosciences (MBX) Fairly Valued As New Leadership Takes Charge?Moomoo · July 16, 2026Truist Financial Maintains MBX Biosciences(MBX.US) With Buy RatingSimply Wall Street · July 14, 2026How MBX Biosciences’ New CEO-Chairman Structure Could Reframe the MBX Investment NarrativeMoomoo · July 14, 2026Press Release: MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of GrowthInside INdiana Business · July 14, 2026Carmel-based MBX Biosciences makes leadership changesInvesting.com · July 13, 2026MBX Biosciences stock falls on CEO and CFO leadership changeswww.marketscreener.com · July 13, 2026MBX Biosciences, Inc. Announces the Appointment of John Smither as Chief Financial Officer, Effective July 13, 2026
Benzinga · December 4, 2025Goldman Sachs Initiates Coverage On MBX Biosciences with Sell Rating, Announces Price Target of $18
Mt Newswire · December 4, 2025Goldman Sachs Initiates Coverage on MBX Biosciences With Sell Rating, $18 Price Target
Mt Newswire · November 4, 2025TD Cowen Initiates MBX Biosciences at Buy
Mt Newswire · October 21, 2025Mbx Biosciences Insider Bought Shares Worth $272,790, According to a Recent SEC Filing

Peers

S&P 500SPX · $7,457.69-1.01%Cytokinetics, IncorporatedCYTK · $80.18-0.22%ImmunityBio, Inc.IBRX · $7.68+3.09%Nuvalent, Inc.NUVL · $123.960.00%Kymera Therapeutics, Inc.KYMR · $115.77+1.56%Protagonist Therapeutics, Inc.PTGX · $140.91+6.73%Apogee Therapeutics, Inc.APGE · $134.00-0.06%Praxis Precision Medicines, Inc.PRAX · $314.41+2.01%Spruce Biosciences, Inc.SPRB · $43.54-1.67%Inhibrx Biosciences Inc.INBX · $87.39-1.89%Zenas BioPharma, Inc.ZBIO · $29.53+4.57%Halozyme Therapeutics, Inc.HALO · $77.81+0.35%